Gao Fu, the head of China's CDC, led the development of a protein subunit vaccine that was approved by regulators last week for emergency use, the Chinese Academy of Sciences’ Institute of Microbiology said in a statement Monday.

It is the fourth such vaccine to be given emergency use approval. China has approved four vaccines developed by three Chinese companies for general use.

Also read: EU regulator approves J&J’s one-shot COVID-19 vaccine

The vaccine was developed jointly by Anhui Zhifei Longcom Biopharmaceutical Co. Ltd. and the Chinese Academy of Sciences. The team finished phase 1 and phase 2 clinical trials in October of last year and is currently conducting the last phase of trials in Uzbekistan, Pakistan and Indonesia, according to the statement.

The vaccine was approved for use in Uzbekistan on March 1.

The protein subunit vaccine is similar to many of the other vaccines that have been approved globally in that it trains the body to recognize the spike protein that covers the surface of the coronavirus vaccine, although the difference lies in how it tells the body to recognize the protein. Scientists grow a harmless version of the protein in cells and then purify it, before it is assembled into a vaccine and injected.

There is no publicly available information in peer-reviewed scientific journals about the clinical trial data showing efficacy or safety. A spokesperson for the company said that the data could not be shared at this time but that the company was actively providing the information to health authorities.

Also read: Covishield and Covaxin: What we know about India's Covid-19 vaccines

China has been slow in vaccinating its population of 1.4 billion people, despite having four vaccines approved for general use. The latest numbers, according to government officials at a press briefing Monday in Beijing, is that it has administered 64.98 million doses of vaccines.

China has targeted what it considers key populations for vaccination thus far, namely health care workers as well as those who work at the border or customs, and specific industries the government has selected. A second group, which has notably been absent thus far in comparison to many other countries, has been the elderly and those with pre-existing conditions.

The vaccines have previously been limited to adults 18-59 years old, as officials cited a lack of clinical trial data for those who are older, although the government appears to be signaling the limits are now being set aside. “We will promptly carry out mass vaccination of relevant populations,” Li Bin, a vice chair on the National Health Commission, said Monday.

China's official Xinhua News Agency reported over the weekend that in certain neighborhoods in Beijing, local health centers started to offer the vaccines to those aged 60 and

Also read: S. Korea approves AstraZeneca COVID-19 vaccine for all adults